Home Newsfeeds Fanhua Sees Q4 Revenue No Less Than RMB 30M

Fanhua Sees Q4 Revenue No Less Than RMB 30M

Business Outlook Fanhua expects its operating income to be no less than RMB30.0 million for the fourth quarter of 2022. This forecast is based on the current market conditions and reflects Fanhua's

byMichael Horton

November 21, 2022

1 minute read

Business Outlook

Fanhua expects its operating income to be no less than RMB30.0 million for the fourth quarter of 2022. This forecast is based on the current market conditions and reflects Fanhua’s preliminary estimate, which is subject to change caused by various factors.

Is Tencent Winding Down Its Big Investments?

By The Bamboo Works

August 24, 11:29 AM

Key Takeaways: Reuters reported Tencent might sell some or all of its Meituan holdings this year, though Tencent called the report ‘inaccurate’ Some think Tencent might sell other stakes in its more than 70 U.S.- and Hong Kong-listed portfolio companies to raise funds to buy back its shares By Fai Pui

BABA

Barclays Maintains Overweight on PowerSchool Holdings, Raises Price Target to $19

By Benzinga Newsdesk

August 9, 7:55 AM

Barclays analyst Saket Kalia maintains PowerSchool Holdings (NYSE:PWSC) with a Overweight and raises the price target from $18 to $19.

PWSC

Credit Suisse Assumes Walmart at Outperform, Announces Price Target of $170

By Benzinga Newsdesk

December 20, 6:26 AM

Credit Suisse analyst Karen Short assumes Walmart (NYSE:WMT) with a Outperform rating and announces Price Target of $170.

WMT

Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients

By Vandana Singh

June 3, 10:27 AM

Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3 trials are now underway for melanoma and non-small cell lung cancer.

MRK

Fanhua Sees Q4 Revenue No Less Than RMB 30M

Related Posts

Is Tencent Winding Down Its Big Investments?

Barclays Maintains Overweight on PowerSchool Holdings, Raises Price Target to $19

Credit Suisse Assumes Walmart at Outperform, Announces Price Target of $170

Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients